Abstract:Seho Kweon, 1, 2 Seong Jin Park, 3 Ha Kyeong Lee, 1 Seo Hee Kang, 4 Kwan-Young Chang, 4 Jeong Uk Choi, 5 Jooho Park, 6 Jung-Hyun Shim, 7 Jin Woo Park, 7 Youngro Byun 1, 3 1 Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea; 2 College of Pharmacy, Chonnam National University, Gwangju, 61186, Republic of Korea; 3 College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea; 4 Global R&D Center, IcureBNP, Seoul, 06170, Republic of Korea; 5 College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea; 6 Department of Biomedical & Health Science, Konkuk University, Chungju, 27478, Republic of Korea; 7 College of Pharmacy and Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam, 58554, Republic of Korea Correspondence: Jin Woo Park; Youngro Byun, Tel +82 61 450 2704, Email ; Background: For maintenance therapy in type 2 diabetes, glucagon-like peptide-1 agonist (GLP-1A), which exhibits low cardiovascular risk and high efficacy, is a promising peptide therapeutic. However, developing an oral GLP-1A presents challenges due to the analog's poor cellular permeability and gastrointestinal (GI) stability. Methods: To mitigate such limitations, an oral nanoformulation of liraglutide (LG) was designed and achieved by combining LG with bile acid derivatives using the nanoprecipitation method. This strategy allowed the bile acid moieties to localize at the nanoparticle surface, enhancing the binding affinity for apical sodium-dependent bile acid transporter (ASBT) and improving GI stability. The in vitro characteristics, cellular permeability, and absorption mechanisms of the LG nanoformulation (LG/TD-NF) were thoroughly investigated. Furthermore, the in vivo oral absorption in rats and the glucose-lowering effects in a diabetic ( db/db ) mouse model were evaluated. Results: The LG/TD-NF produced neutral nanoparticles with a diameter of 58.7 ± 4.3 nm and a zeta potential of 4.9 ± 0.4 mV. Notably, when exposed to simulated gastric fluid, 65.7 ± 3.6% of the LG/TD-NF remained stable over 120 min, while free LG was fully degraded. Relative to unformulated LG, the Caco-2 cellular permeability of the nanoformulation improved, measuring 10.9 ± 2.1 (× 10 − 6 cm/s). The absorption mechanism prominently featured endocytosis simultaneously mediated by both ASBT and epidermal growth factor receptor (EGFR). The oral bioavailability of the LG/TD-NF was determined to be 3.62% at a dosage of 10 mg/kg, which is 45.3 times greater than that of free LG. In a diabetes model, LG/TD-NF at 10 mg/kg/day exhibited commendable glucose sensitivity and reduced HbA1c levels by 4.13% within 28 days, similar to that of subcutaneously administered LG at a dosage of 0.1 mg/kg/day. Conclusion: The oral LG/TD-NF promotes ASBT/EGFR-mediated transcytosis and assures cellular permeability within the GI tract. This method holds promise for the development of oral GLP-1A peptides as an alternative to injections, potentially enhancing patient adherence to maintenance therapy. Keywords: nanoformulation of GLP-1A, oral liraglutide, ASBT-mediated endocytosis, EGFR Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by inadequate insulin production, and in some instances, a decline in insulin sensitivity as the condition progresses. 1 Orally administered pharmacological agents, such as metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors, are extensively utilized as potential therapeutic interventions for T2DM management in the context of long-term treatment. Moreover, injectable therapeutic peptides, including glucagon-like peptide-1 agonist (GLP-1A) and insulin, often serve as primary treatment modalities. 2,3 Due to their superior glucose-lowering effects and reduced cardiovascular risks compared to chemical-based medications, these therapeutic peptides have garnered significant attention in drug development. Thus, there is an intensified focus on advancing synthesis and purification technologies to further the development of these peptides. 4 However, the need for prolonged and frequent invasive administration can lead to decreased patient compliance and heightened risk for infections, potentially resulting in treatment failure. Several modified forms of GLP-1A have been introduced to mitigate these limitations. Some of these have extended half-lives, such as liraglutide (LG), lixisenatide, albiglu -Abstract Truncated-

Enhancing the Therapeutic Efficacy of GLP-1 for Hyperglycemia Treatment: Overcoming Barriers of Oral Gene Therapy with Taurocholic Acid-Conjugated Protamine Sulfate and Calcium Phosphate

Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation.

In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

Surface Coating Approach to Overcome Mucosal Entrapment of DNA Nanoparticles for Oral Gene Delivery of Glucagon-like Peptide 1.

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes

Emerging Technologies to Achieve Oral Delivery of GLP-1 and GLP-1 Analogs for Treatment of Type 2 Diabetes Mellitus (T2DM)

Plasmid DNA Nanoparticles for Nonviral Oral Gene Therapy

181-OR: Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes

One‐Pot Synthesis of PEGylated Lipoplexes to Facilitate Mucosal Permeation for Oral Insulin Gene Delivery

Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract

Efficient, Glucose Responsive, and Cell-Specific Transgene Expression in Pancreatic Islets.

Metformin booster adipocyte-targeted gene therapy for the treatment of obesity and related metabolic syndromes

A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

Improved Oral Delivery of Insulin by PLGA Nanoparticles Coated with 5Β-Cholanic Acid Conjugated Glycol Chitosan

Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (Teduglutide) - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome

Advancements in Oral Insulin: A Century of Research and the Emergence of Targeted Nanoparticle Strategies

PLL-alginate and the HPMC-EC hybrid coating over the 3D DNA nanocubes as compact nanoparticles for oral administration